Evaluation of teicoplanin concentrations and safety analysis in neonates.

[1]  K. Tomono,et al.  Loading regimen required to rapidly achieve therapeutic trough plasma concentration of teicoplanin and evaluation of clinical features , 2012, Clinical pharmacology : advances and applications.

[2]  P. Matthews,et al.  Teicoplanin levels in bone and joint infections: are standard doses subtherapeutic? , 2007, The Journal of infection.

[3]  A. Fraise,et al.  Guidelines for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the UK. , 2006, The Journal of antimicrobial chemotherapy.

[4]  Judith R. Campbell,et al.  Emergence of new strains of methicillin-resistant Staphylococcus aureus in a neonatal intensive care unit. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  N. Matsuura,et al.  Population Pharmacokinetics of Arbekacin, Vancomycin, and Panipenem in Neonates , 2004, Antimicrobial Agents and Chemotherapy.

[6]  Jane Alcorn,et al.  Pharmacokinetics in the newborn. , 2003, Advanced drug delivery reviews.

[7]  J. López‐Herce,et al.  Teicoplanin pharmacokinetics in critically ill paediatric patients. , 1999, The Journal of antimicrobial chemotherapy.

[8]  Sean C. Sweetman.  Martindale: The Complete Drug Reference , 1999 .

[9]  V. Fanos,et al.  A review of teicoplanin in the treatment of serious neonatal infections , 1997, European Journal of Pediatrics.

[10]  Elazer R. Edelman,et al.  Adv. Drug Delivery Rev. , 1997 .

[11]  R. Frye,et al.  Teicoplanin Nephrotoxicity: First Case Report , 1992, Pharmacotherapy.

[12]  W. S. St. Peter,et al.  Teicoplanin measurement in patients with renal failure: comparison of fluorescence polarization immunoassay, microbiological assay, and high-performance liquid chromatographic assay. , 1991, Therapeutic drug monitoring.

[13]  D. Wyllie,et al.  Increased teicoplanin doses are associated with improved serum levels but not drug toxicity. , 2014, The Journal of infection.

[14]  H. Ikeuchi,et al.  Evaluation of teicoplanin dosing designs to achieve a new target trough concentration , 2012, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[15]  K. Yanagihara,et al.  Criteria for safety evaluation of antimicrobial agents , 2011, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[16]  R. Grũneberg,et al.  Teicoplanin. The First Decade. , 1997 .